SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,720.00 in Stock

Key Points

• Insider sale: Zhenyu Xu sold 4,000 SOPHiA GENETICS shares for $28,720 under a pre-arranged Rule 10b5-1 plan, reducing their ownership by 0.73% while retaining 541,493 shares.
• Stock and financial performance: Shares traded at $7.06, near the middle of their 12-month range. The company missed quarterly EPS expectations, reporting a loss of $0.26 per share, though revenue exceeded estimates at $23.31 million.
• Analyst outlook: Wall Street’s consensus rating is Hold, with an average price target of $10.00; ratings include three Buys, one Hold and one Sell.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 4,000 shares of the firm's stock in a transaction dated Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total value of $28,720.00. Following the completion of the sale, the insider directly owned 541,493 shares in the company, valued at approximately $3,887,919.74. The trade was a 0.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.12, for a total value of $60,039.28.
• On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total transaction of $89,100.00.
• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00.

SOPHiA GENETICS Trading Down 0.4%

SOPHiA GENETICS stock traded down $0.03 during trading on Wednesday, reaching $7.06. The company had a trading volume of 376,763 shares, compared to its average volume of 310,258. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The stock's 50 day moving average price is $7.95 and its two-hundred day moving average price is $6.20. The firm has a market capitalization of $592.26 million, a price-to-earnings ratio of -6.14 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors have recently modified their holdings of the company. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth approximately $9,809,000. Principal Financial Group Inc. raised its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Sei Investments Co. acquired a new position in SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC lifted its position in SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock valued at $1,117,000 after buying an additional 17,406 shares in the last quarter. Hedge funds and other institutional investors own 31.59% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of SOPHiA GENETICS in a research report on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.